Cell cycle, mitosis and therapeutic applications;Cycle cellulaire, mitose et applications thérapeutiques

Bulletin du Cancer

Volumn 98, Issue 9, 2011, Pages 1037-1045

  Levy, Antonin ^a   Albiges Sauvin, Laurence ^a   Massard, Christophe ^a   Soria, Jean Charles ^a   Deutsch, Éric ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Apoptosis; Cell cycle; Checkpoint

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; GENOMIC DNA;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL DEATH; DNA DAMAGE; DNA REPAIR; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; MITOSIS; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 80053542405     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1382     Document Type: Review

References (43)

1. Meijer L. The cell division cycle and its regulation. Bull Cancer 2006 ;HS : 41-53.
2. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246 : 629-34. (Pubitemid 19283354)
3. Pourquier P, Robert J. Vue générale de la réparation de l'ADN. Bull Cancer 2011; 98 : 229-37.
4. Dassonneville L, Bailly C. Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs. Bull Cancer 1998; 85 : 254-61. (Pubitemid 28198376)
5. Koundrioukoff S, Polo S, Almouzni G. Interplay between chromatin and cell cycle checkpoints in the context of ATR/ATM-dependent checkpoints. DNA Repair (Amst) 2004; 3 : 969-78. (Pubitemid 38997939)
6. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421 : 499-506. (Pubitemid 36168436)
7. Hennequin C, Quero L, Favaudon V. Réparation cellulaire et radiosensibilité tumorale : focus sur le gène ATM. Bull Cancer 2011; 98 : 239-46.
8. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science 2001; 294 : 1713-6. (Pubitemid 33104841)
9. Chen Y, Poon RY. The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci 2008; 13 : 5016-29. (Pubitemid 351599655)
10. O'Driscoll M. Mouse models for ATR deficiency. DNA Repair (Amst) 2009; 8 : 1333-7.
11. Shechter D, Costanzo V, Gautier J. ATR and ATM regulate the timing of DNA replication origin firing. Nature Cell Biol2004; 6 : 648-55. (Pubitemid 38960923)
12. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ADNsb complexes. Science 2003; 300 : 1542-8. (Pubitemid 36682880)
13. Canman CE. Checkpoint mediators: relaying signals from DNA strand breaks. Curr Biol 2003; 13 : R488-90. (Pubitemid 36726031)
14. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nature Rev Cancer 2003; 3 : 155-68. (Pubitemid 37328868)
15. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432 : 316-23. (Pubitemid 39551659)
16. Löffler H, Bochtler T, Fritz B, et al. DNA damage-induced accumulation of centrosomal Chk1 contributes to its checkpoint function. Cell Cycle 2007; 6 : 2541-8. (Pubitemid 350058673)
17. Wahl GM, Carr AM. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nature Cell Biol 2001; 3 : E277-86. (Pubitemid 33130452)
18. Busino L, Chiesa M, Draetta GF, Donzelli M. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 2004; 23 : 2050-6. (Pubitemid 38496734)
19. Agner J, Falck J, Lukas J, Bartek J. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp Cell Res 2005; 302 : 162-9. (Pubitemid 39550459)
20. Carassou P, Meijer L, Le Moulec S, Aoun O, Bengrine-Lefevre L. Le cycle cellulaire et ses cibles : inhibition des CDK. Bull Cancer 2011 [Epub ahead of print].
21. Liu P, Barkley LR, Day T, et al. The Chk1-mediated S-phase checkpoint targets initiation factor Cdc45 via a Cdc25A/Cdk2-independent mechanism. J Biol Chem 2006; 281 : 30631-44. (Pubitemid 44582091)
22. Antoccia A, Sakamoto S, Matsuura S, Tauchi H, Komatsu K. NBS1 prevents chromatid-type aberrations through ATM-dependent interactions with SMC1. Radiat Res 2008; 170 : 345-52.
23. Segurado M, Tercero JA. The S-phase checkpoint: targeting the replication fork. Biol Cell 2009; 101 : 617-27.
24. Löbrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 2007; 7 : 861-9. (Pubitemid 350006255)
25. Teyssier F, Bay JO, Dionet C, Verrelle P. Cell cycle regulation after exposure to ionizing radiation. Bull Cancer 1999; 86 : 345-57. (Pubitemid 29230826)
26. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20 : 1803-15. (Pubitemid 32458690)
27. Sudakin V, Yen TJ. Targeting mitosis for anti-cancer therapy. Bio-Drugs 2007; 21 : 225-33. (Pubitemid 47104978)
28. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004; 64 : 2502-8. (Pubitemid 38523906)
29. Cheung HW, Chun AC, Wang Q, et al. Inactivation of human MAD2B in nasopharyngeal carcinoma cells leads to chemosensitization to DNA-damaging agents. Cancer Res 2006; 66 : 4357-67.
30. Mitchison T, Kirschner M, Authors FN, et al. Dynamic instability of microtubule growth. Nature 1984; 312 : 237-42. (Pubitemid 15201998)
31. Mareel MM, De Brabander MJ. Effect of microtubule inhibitors on malignant invasion in vitro. J Natl Cancer Inst 1978; 61 : 787-92. (Pubitemid 9029109)
32. Crossin KL, Carney DH. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 1981; 27 : 341-50. (Pubitemid 12200503)
33. Kelling J, Sullivan K, Wilson L, Jordan MA. Suppression of centromere dynamics by Taxol in living osteosarcoma cells. Cancer Res 2003; 63 : 2794-801. (Pubitemid 36667150)
34. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009; 14 : 559-70.
35. Syed N, Smith P, Sullivan A, et al. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 2006; 107 : 250-6. (Pubitemid 43053549)
36. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003; 161 : 267-80. (Pubitemid 36529846)
37. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008 ; 1786 : 60-72.
38. Liu ST, Rattner JB, Jablonski SA, et al. Mapping the assembly pathways that specify formation of the trilaminar kinetochore plates in human cells. J Cell Biol 2006; 175 : 41-53. (Pubitemid 44537197)
39. Long ZJ, Xu J, Yan M, et al. ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture. Cell Cycle 2008; 7 : 1473-9. (Pubitemid 351872587)
40. Kaelin Jr WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5 : 689-98. (Pubitemid 41486362)
41. Sur S, Pagliarini R, Bunz F, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 2009; 106 : 3964-9.
42. Tao Y, Zhang P, Frascogna V, et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007; 97 : 1664-72. (Pubitemid 350249356)
43. Tao Y, Leteur C, Yang C, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 2009; 8 : 1196-205.